company background image
ETON

Eton Pharmaceuticals NasdaqGM:ETON Stock Report

Last Price

US$3.04

Market Cap

US$76.9m

7D

2.4%

1Y

-24.6%

Updated

07 Dec, 2022

Data

Company Financials +
ETON fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ETON Stock Overview

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases.

Eton Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eton Pharmaceuticals
Historical stock prices
Current Share PriceUS$3.04
52 Week HighUS$4.78
52 Week LowUS$1.95
Beta1.44
1 Month Change21.12%
3 Month Change33.83%
1 Year Change-24.57%
3 Year Change-49.59%
5 Year Changen/a
Change since IPO-51.36%

Recent News & Updates

Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous

Sep 13

Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story

Aug 14

Recent updates

Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Apr 15
Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Oct 14
Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Aug 18
What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner

May 15
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Apr 05
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

Mar 01
Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit

Jan 07
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit

Do Insiders Own Lots Of Shares In Eton Pharmaceuticals, Inc. (NASDAQ:ETON)?

Jul 06
Do Insiders Own Lots Of Shares In Eton Pharmaceuticals, Inc. (NASDAQ:ETON)?

Shareholder Returns

ETONUS PharmaceuticalsUS Market
7D2.4%0.5%-0.4%
1Y-24.6%13.2%-20.6%

Return vs Industry: ETON underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.

Return vs Market: ETON underperformed the US Market which returned -20.6% over the past year.

Price Volatility

Is ETON's price volatile compared to industry and market?
ETON volatility
ETON Average Weekly Movement9.9%
Pharmaceuticals Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: ETON is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ETON's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201717Sean Brynjelsenhttps://www.etonpharma.com

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis.

Eton Pharmaceuticals, Inc. Fundamentals Summary

How do Eton Pharmaceuticals's earnings and revenue compare to its market cap?
ETON fundamental statistics
Market CapUS$76.90m
Earnings (TTM)-US$8.89m
Revenue (TTM)US$18.85m

4.1x

P/S Ratio

-8.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ETON income statement (TTM)
RevenueUS$18.85m
Cost of RevenueUS$4.96m
Gross ProfitUS$13.88m
Other ExpensesUS$22.78m
Earnings-US$8.89m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.35
Gross Margin73.67%
Net Profit Margin-47.19%
Debt/Equity Ratio57.1%

How did ETON perform over the long term?

See historical performance and comparison